IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 317 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,422,361 | +104.0% | 362,045 | +84.5% | 0.02% | +112.5% |
Q2 2023 | $8,050,619 | +160.0% | 196,213 | +126.4% | 0.01% | +166.7% |
Q1 2023 | $3,096,907 | -72.6% | 86,651 | -71.0% | 0.00% | -75.0% |
Q4 2022 | $11,301,955 | +22.0% | 299,231 | +42.9% | 0.01% | +9.1% |
Q3 2022 | $9,264,000 | +97.6% | 209,445 | +65.4% | 0.01% | +120.0% |
Q2 2022 | $4,688,000 | -4.1% | 126,621 | -21.2% | 0.01% | +25.0% |
Q4 2021 | $4,889,000 | +15.6% | 160,659 | +27.4% | 0.00% | 0.0% |
Q3 2021 | $4,230,000 | +26.9% | 126,106 | +50.9% | 0.00% | +33.3% |
Q2 2021 | $3,333,000 | +336.3% | 83,566 | +391.4% | 0.00% | – |
Q1 2021 | $764,000 | -77.9% | 17,006 | -72.2% | 0.00% | -100.0% |
Q4 2020 | $3,461,000 | -73.1% | 61,217 | -77.4% | 0.00% | -76.9% |
Q3 2020 | $12,857,000 | +35.7% | 270,949 | +68.6% | 0.01% | +8.3% |
Q2 2020 | $9,474,000 | +213.6% | 160,672 | +151.5% | 0.01% | +140.0% |
Q1 2020 | $3,021,000 | -91.5% | 63,896 | -89.1% | 0.01% | -87.8% |
Q4 2019 | $35,537,000 | -31.7% | 588,258 | -32.3% | 0.04% | -35.9% |
Q3 2019 | $52,025,000 | +4.9% | 868,390 | +12.5% | 0.06% | +3.2% |
Q2 2019 | $49,607,000 | +4.1% | 771,859 | +31.4% | 0.06% | +1.6% |
Q1 2019 | $47,662,000 | +114.7% | 587,191 | +43.0% | 0.06% | +96.8% |
Q4 2018 | $22,202,000 | +269.4% | 410,699 | +252.5% | 0.03% | +342.9% |
Q3 2018 | $6,010,000 | +1071.5% | 116,515 | +847.3% | 0.01% | +600.0% |
Q2 2018 | $513,000 | -53.0% | 12,300 | -50.3% | 0.00% | 0.0% |
Q1 2018 | $1,092,000 | -72.7% | 24,762 | -68.8% | 0.00% | -83.3% |
Q4 2017 | $3,998,000 | +18.5% | 79,485 | +19.4% | 0.01% | +20.0% |
Q3 2017 | $3,375,000 | +23.2% | 66,568 | +23.6% | 0.01% | 0.0% |
Q2 2017 | $2,740,000 | +227.4% | 53,864 | +158.8% | 0.01% | +400.0% |
Q1 2017 | $837,000 | -73.7% | 20,816 | -68.7% | 0.00% | -80.0% |
Q4 2016 | $3,186,000 | +153.7% | 66,604 | +94.4% | 0.01% | +150.0% |
Q3 2016 | $1,256,000 | +26.5% | 34,270 | -19.6% | 0.00% | 0.0% |
Q2 2016 | $993,000 | -22.2% | 42,616 | +35.3% | 0.00% | 0.0% |
Q1 2016 | $1,276,000 | -58.7% | 31,500 | -36.8% | 0.00% | -60.0% |
Q4 2015 | $3,086,000 | – | 49,824 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |